DocumentsDate added
Research article:
Kashyap Shah1,*,Prasanna Ku. Pradhan2,Shreya R Shah2
Affiliation:-
1Department of Quality Assurance, Sigma Institute of Pharmacy, Bakrol, Vadodara, Gujarat, India
2H.O.D, Department of Quality Assurance, Sigma Institute of Pharmacy, Bakrol, Vadodara, Gujarat, India
3Department of Quality Assurance, Sigma Institute of Pharmacy, Bakrol, Vadodara, Gujarat, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Quality Assurance, Sigma Institute of Pharmacy, Bakrol, Vadodara, Gujarat, India
Abstract
A simple high-performance liquid chromatography (HPLC) method has been developed and validated for the simultaneous determination of ondansetron (ONDA) and dexamethasone (DEXA) in UV and HPLC. Method was performed using an Enable C18 G column. (150 mm × 4.6 mm, 5 μm: Spinco Biotech Pvt Ltd) and Enable C18 Luna (150 mm × 4.6 mm, 5 μm). The mobile phase consisted of Methanol, acetonitrile and water in ratio 60:10:30 V/V (pH 5.5 with 10% ortho phosphoric acid) at a flow rate of 1.0 ml/min. The method was validated under the range from 50-8000ng/ml for both ONDA and DEXA. The absolute recovery of ONDA ranged from 98.0 to 105.28% while DEXA recoveries ranged from 99.0 to 102.63%.
Keywords: Ondansetron; Dexamethasone; Validation; UV; HPLC
*To whom it corresponds:-
Kashyap Kiritbhai Shah,
Department of Quality Assurance, Sigma Institute of Pharmacy, Bakrol, Vadodara, Gujarat, India
Mo No: 9998978515
9016206961
REFERENCES
1.http://www.clinicaltrial.gov.in/phase-3Trials/Ondansetrone&Dexamethasone,date accessed on 23-06-2013.
2.http://www.clinicalresearch.gov.in/external/socrel/content/hplc.html,date accessed on 05-07-2013.
3.http://www.chemistry.adelaide.edu.au/external/socrel/content/hplc.html,date accessed on 23-06-2013.
4.Drug bank, Drug profile, Ondansetrone ,2013.
5.http://www.drugbank.ca/drugs/DB06203, date accessed on 25-06-2013.
6.Drug bank, Drug profile, Dexamethasone, 2013.
7.http://www.drugbank.ca/drugs/DB06165, 2012.
8.Shethi PD, HPLC-Quantitative analysis of pharmaceutical formulations, 1st edition, CBS publishers & distributors, 2001, 141.
9.ICH, Guidance for Industry, Q1A Stability Testing of New Drug Substances and Products. ICH-Q1A, 2001(August).
10.International Conference on Harmonisation, Guidance for Industry In;
11.Q2B Validation of Analytical Procedures, Methodology, Switzerland, IFPMA, 1996, 1-8.
12.Skoog DA, Holler FJ, Nieman TA, Principles of Instrumental Analysis, Harcourt Asia Pvt Ltd & Harcourt Collage Publishers, 5th edition, 1998, 728-744.
13.Beckett AH, Stenlake JB, UV-visible Spectrophotometry, Practical Pharmaceutical Chemistry, 4th ed, Part-II, C.B.S. Publishers, Delhi, 2001,285-97.
14.Sharma YR, Ultraviolet and visible spectroscopy in Elementary Organic Spectroscopy, 1sted, S. Chand & Company Ltd, New Delhi, 2004, 9-60.
15.Meyer VR, Practical High Performance Liquid Chromatography, 2nded, John wiley and sons, London, 1993, 26 - 258.
16.Kazakevich Y, Lobrutto R, HPLC for Pharmaceutical Scientists, 1sted.John Wiley & Sons Inc, Hoboken New jersey, 2007.
17.Snyder LR., Kirkland JL, Glajch JL, Practical HPLC Method Development, New York, Wiley, 1997
18.The United States Pharmacopoeia 30 NF 25, The US Pharmacopoeial Convention, 2009, 2001.
19.The British Pharmacopoeia, The Stationary office on behalf of the Medicines and Healthcare products Regulatory Agency, 2011, 2, 2146.
20.The United States Pharmacopoeia 30 NF 25, The US Pharmacopoeial Convention. 2009,3082.
21.The British Pharmacopoeia, The Stationary office on behalf of the Medicines and Healthcare products Regulatory Agency, 2011,2,5107.
22.Government of India, Ministry of Health and Family Welfare, The Indian pharmacopoeia, The Indian Pharmacopoeia Commission, Ghaziabad,2010:287.
23.Mushabbarbasha MD, and Srinidhi M, Devlopment and Validation Of Ondansetrone In Bulk and Dosage Form. International Journal of Tech Research,2013, 5(1), 86-98.
24.Singh Pradeep Kumar and Dinda S, Devlopment and Validation OfOndansetrone in Films” International Journal Of Pharmaceutical Science, 2013;3(1):57-66.
25.Kalaichelvi R, and MADHAVA RAO M, “Spectrophotometric Method of Ondansetrone Hydrochloride Formulation”, International Journal of Pharmacy and Pharmaceutical Science, 2012;4(1):1491.
26.Dedania Z, Dedania R and Baldania M, Simultaneous Estimation of omeprazole & ondansetrone, Asian Journal of Research Chemistry, 2009;2(2):108-111.
27.Renuka GN and Rahaman H, Sepectrophotometric Method for the Estimation of Dexamethasone Sodium Phosphate. Indo Americal Journal of Pharmaceutical Research, 2013; 3:7103-7113.
28.PravinKumar P and Murlikrisna M, Derivative Spectrometric Estimation of Ondansetrone and Paracetamol.2006;3(3):134-136.
29.Smita M and Priya P, “Simultaneous Estimation of Ondansetrone and Pantoprazole. IOSR Journal of Pharmacy and Biological Science, 2012;4(3):05-08.
30.Raval PB, Puranik M and Wadher SJ, Indian Journal of Pharmaceutical Science. 2013:133-143.
31.Singh Pradeep Kumar, and Dinda S, Development and Validation Of Ondansetrone in Films. International Journal Of Pharmaceutical Science, 2013; 3(1):57-66.
32.Imran A, Jat RK and Varnika S, Development & validation of RP-Hplc Method of ondansetrone hydrochloride & it`s Bulk Drug, IRJP,2012;3(2):111-113.
33.Menyananthan YN, Krisnanveni N, Babu B, and Suresh B, Simultaneous estimation of ondansetrone and ranitidine in pharmaceutical formulation,Indian Journal of Pharmaceutical Science, 2012; 1(2):129-132.
34.ViswewaraRao K, Padmaja Reddy K and Kalyan K, simultaneos trace level quantification of Glyoxol in ondansetrone Hydrochloride, journal of pharmaceutical science, 2012;5(12):5449-5452.
35.Garcia CV, Breier AR, Steppe M and Oppe TP, J. Pharma Biomed Anal, 2013; 31(3):597-600.
36.Prakash K, Katakam S and Kumari R, International Journal of Pharmacy and Pharmaceutical Science, 2012; 4: 505.
37.Gracia CV, Breier AR, Steppe M and Oppe TP, “Determination of dexamethasone acetate in cream by Hplc” journal of Pharma Biomed Anal, 2003; 31(3): 597-600.
38.Katakam P and Sireesha K, Simultaneous Determination of Dexamethasone Sodium Phosphaate and Chloramphenicol In Bulk and Formulation. Int J Pharm Pharm Sci, Vol 4, Suppl 4, 505-510.
39.Chen Q, Zielinski D, Chen J, Koski A and Nowak S, US National Library of Medicine National Institute of Health, 2008;48(3):792.
40.Heda A, Kathiriya M and Puranik P, Simultaneous Determination of Granisetrone and Dexamethasone, Indian Journal of Pharmaceutical Science, 2011: 73(6); 696-699.
41.Melojevic Z, Agbaba D, and Ristic P, High Performance Chromatography of Dexamethasone and Xylometazoline in Nasal Drops, Journal of Pharma Biomed Anal, 2002; 949(1-2):79-82.
42.Dabhi MJ, Patwari AH, Desai AH and Doshi DB, Simultaneous Determination of Moxifloxacin Hydrochloride and Dexamethasone Hydrochloride in Eye Drops, Journal of Chemical and Pharmaceutical Research, 2012;4(10): 4462-4467.
43.Maria Cristina Urban, Rubjana Mainardes and Maria Gramio, Devlopment and Validation of Dexamethasone Acetate in Microemulsion. Braz. J. Pharm. Sci.2009; 45(1):87-92.
44.Kang Ping Xiao, Yuan Xiao and Rustam Abu M, Trace Betamethasone or Dexamethasone in Betamethasone or Dexamethasone by Reversed Phase Hplc. journal of chromatographic science, 2008, 46.
45.Desai Urvish H, PtwariArpit H, and Bhanubhai N, “Simultaneous Estimation of Ciprofloxacin & Dexamethasone, International Journal of Pharmaceutical Science & Research, 2013;5(2):62-66.
46.Syed Naeem R, Marima I and Ullah Khan I, Determination of Sparfloxacin & Dexamethasone in Formulation, Brazilian Journal of Pharmaceutical Science & Research, 2313;49(2).
47.http//Drugs@FDA, date accessed on 06-07-2013.
48.http//www.drugsupdate.com/generic/view/516, date accessed on 14-07-2013.
49.http//www.medilexicon.com/drugs/xenazine.php, date accessed on 18-07-2013.
50.http//www.virtualmedicalcentre.com/drugs/tetrabenazine/3135, date accessed on 23-07-2013
51.http//www.drugbank.com/DB04844, date accessed on 12-08-2013.
52.http//www.sigma-aldrich.com, date accessed on 12-08-2013.
53.http//www.wikipedia.org, date accessed on 12-08-2013.
54.http//www.standardbase.com,accessed on 15-08-2013.
Abbreviation:- ODA: Ondansetron , DEXA; Dexamethasone, UV:Ultra violet,Abs:Absorption, (HPLC):High-Performance Liquid Chromatography, Conc: Concentration.
Article citation:
SHAH KK, Pradhan PK,Shah SR., Analytical Method Development and validation for simultaneous estimation of ondansetron and dexamethasone in synthetic mixture. J Pharm Biomed Sci 2014;04(05):448-458. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Shah KK., Pradhan PK, Shah SR., This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Review article
Nagi Idris1,*,Faraj E Homry Mohamed2,Manzoor A Thokar3
Affiliation:-
1 Faculty of Pharmacy,Omer Al Mukhtar University, Albeda, Libya
2 Faculty of Medicine Omar Al Mukhtar University, Albeida, Libya
3Professor & Head Microbiology, Faculty of Pharmacy Omer Al Mukhtar University, Albeda, Libya
The name of the department(s) and institution(s) to which the work should be attributed:
Omer Al Mukhtar University, Albeda, Libya
*To whom it corresponds:-
Dr Manzoor A Thokar.
Professor & Head Microbiology, Faculty of Pharmacy , Omer Al Mukhtar University, Albeda, Libya
Contact number:+218 944828775
Abstract:
Our main antibiotic weaponry such as 3rdgeneration cephalosporin’s (ceftazidime, ceftriaxone, cefperazone, cefotaxime to name a few) and carbapenams (imipenum, merpenam,doripenam etc) are at a stage of extinction due to the onslaught of Esbl(Extended spectram β lactamase & Mbl (metallo ß lactamase) enzyme inactivation’s by way of hydrolysing their beta-lactam ring &resistance originally remaining confined to few germs started disseminating to others irrespective of gram positive, gram negative, cocci or bacilli nature and unfortunately resistance was extended to other antibiotic classes also.
Outbreak producing pathogens such as MRSA, E.coli, Klebsiella, Pseudomonas and VRE, are already causing global havoc with their resistance venom. There is every danger that VISA/GISA (Vancomycin & Glycopeptide intermediate resistant Staphylococcus aureus) may be a full-fledged future VRS (vancomycin resistant Staphylococcus aureus) entity.
Scientific innovations get modified from time to time & so get interpretations. What is logic today may not be applicable tomorrow. We have to change as per the changing times & keep abreast with latest developments & incorporate need based surveillance and research tools like Esbl & Mbl technologies in our systems otherwise wrongs would continue to happen
Global proliferation of antibiotic resistance to microbes is attributed to injudicious use of antibiotics at global, national & local levels. Antibiotic usage has to be rationalized for choice, dose & duration in prophylactic, empirical & therapeutic treatment modalities & antibiotic policies need to be formulated on evidence based medicine.
Keywords: Mbl; Esbl; 3rd G cephalosporine; Carbapenam.
REFERENCES
1.Pier GB, Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious disease 6th edition. New York: Churchill Livingstone; 2005.p 2587-2608. Elsevier, Philadelphia.
2.Govan JR. Pseudomonas, Sternotrophomonas, Burkholderia. In: Colle JG, Fraser AG, Marnion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology 14th ed. Churchill Livingstone; 1996.p. 413-424.
3.Wiblin RT. Nosocomial Pneumonia. In Wenzel RP, editor. Prevention and control of nosocomial infections 3rd ed. Williams and Wilkins; 1997.p. 807-19.
4.Pollack M. Pseudomonas aeruginosa. In Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious disease 4th edition. New York: Churchill Livingstone; 1995.p.1980-2003.
5.Kluytmans J. Surgical infections including burns. In: Wenzel R.P., editor. Prevention and Control of Nosocomial Infections (3rd ed.) Williams and Wilkins; Pennsylvania: 1997. pp. 841–65.
6.Fergie JE, Shema SJ, Lott L, Crawford R, Patrick CC. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin Infect Dis.1994;18:390-4.
7.Bergen GA, Shelhamer JH. Pulmonary infiltrates in cancer patients. New approaches to an old problem. Infect Dis Clin North Am. 1996 Jun; 10:297-326.
8.Latham R and Shaftner W. Hospital epidemiology. In: Encylopedia of Microbiology Vol 2 Chief ed. Lederberg 471 Acad Press London 1992.p 471.
9.Szabó D, Szentandrássy J, Juhász Z, Katona K, Nagy K, Rókusz L.Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumanii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary. Ann Clin Microbiol Antimicrob. 2008 May 30;7:12. doi: 10.1186/1476-0711-7-12.
10.Forbes BA, Sham DF, Weissfeld AS, editors. In Bailey and Scott Diagnostic Microbiology.12th edition Mosby 2007; p. 172-186.
11.Nathisuwan S, Burgess DS, Lewis 11 JS. ESBLs: Epidemiology, detection and treatment. Pharmacotherapy. 2001; 21(8):920-928.
12.Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase producing Pseudomonas aeruginosa in diabetes and cancer patients.Indian J Patho Microbiol.2008Apr-Jun;51(2):200-3.
13.Nordmann P, Poirel L. Emerging carbapenemases in gram negative aerobes. Clin Microbiol Infect.2002 Jun;8(6):321-331.
14.Walsh TR, Toleman MA, Poirel L, Nordman P. Metallo ß–lactamase: the quiet before storm?Clin Microbiol Rev 2005;18:306-25.
15.Hemlatha V, Sekar U, Kamat V. Detection of metallo-beta-lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Microbiol.2005 Aug;122:148-152.
16.Franklin C, Liolios L, Peleg AY.Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory.J Clin Microbiol. 2006 Sep;44(9):3139-44.
17.Mendiratta DK, Deotale V, Narang P.Metallo-beta-lactamase producing Pseudomonas aeruginosa in a hospital from a rural area.Indian J Med Res. 2005 May;121(5):701-3.
18.Andrade SS, Picao RC, Campana EH, Nicoletti AG, Pignatari ACC, Gales AC. Influence of disk preparation on detection of metallo-ß-lactamase producing isolates isolates by combined disc assay. J Clin Microbiol. 2007 Jun;45(6):2058-60. Epub 2007 Apr 4.
19.Pitout J, Gregson DB, Poirel L, MC Clure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol. 2005 Jul;43(7):3129-35.
20.Yan JJ, Wu JJ, Tsai SH, Chaung CL. Comparison of double disk, combined-diskand E-test methods for detecting metallo-beta-lactamases in gram negative bacilli. Diagn Microbiol Infect Dis. 2004 May;49(1):5-11.
21.Pitout JD, Chow BL, Gregson DB, Laupland KB, El Sayed S, Chruch DL. Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates. J Clin Microbiol. 2007 Feb;45(2):294-8. Epub 2006 Nov 22.
22.Marra AR, Pereira CA, AC, Menezes LC, Cal RG, de Souza JM, Edmond MB, Faro C, Wey SB.Blood stream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.Antimicrob Agents Chemother. 2006 Jan;50(1):388-90.
23.Tripathi KD, Essentials of Medical Pharmacology, Antimicrobial Drugs: General Consideration, Jaypee brother’s Medical publishers (P) Ltd: New Delhi,2003;5th edition: 627-640.
24.Madoff LC, Kasper DL. Introduction to Infectious diseases: Host-Parasite interactions. In Braunwald E, Fauci AS, Kasper DL, Hauser SL, Lango DL,Jameson JL,editors.Priniciples of internal Medicine.15th edition.MC Graw Hill 2001;763-67.
25.Medeiros AA. Evolution and dissemination of β–lactamases accelerated by generations of β–lactam antibiotics. Clin Infect Dis 1997; 24 suppl 1:519-45.
26.Bush K. New beta-lactamases in Gram negative bacteria; diversity and impact on selection of antimicrobial therapy. Clinical Infect Dis 2001;32:1085-9.
27.Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure.Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33.
28.Paterson DL, Bonomo RA. Extended spectrum ß–lactamases: A clinical update. Clin Microbiol Rev. 2005; 18: 657-86.
29.Lee K, Lim YS, Yong D, Yum JH, Chong Y.Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp.J Clin Microbiol. 2003 Oct;41(10):4623-9.
30.Jacoby GA, Munoz-Price LS.The new beta-lactamases.N Engl J Med. 2005 Jan 27;352(4):380-91.
31.Lee, K., J. B. Lim, J. H. Yum, D. Yong, Y. Chong, J. M. Kim, and D. M. Livermore. 2002. blaVIM-2 cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob. Agents Chemother. 46:1053-1058.
32.Watanabe M, Iyobe S, Inoue M and Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother.1991;35:147-151.
33.Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horri T, Ito H, Yooshimura Fand Kato N. Molecular characterization of an enterobacterial metallo-beta-lactamase found in a clinical isolate of Serratia masrcescens that shows imipenem resistance. Antimicrob Agents Chemother.1994;38:71-78.
34.Laurelli L, Riccio ML, Mazzariol, Cornaglia G, Amicosante G, Fontana R and Rossolini GM. Cloning and characterization of blaVIM, a new integron-borne metallo-ß-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43:1584-90.
35.Tsakris A, Pournaras S, Neil W, Marie-France J, Babini GS, John D, David ML. Outbreak of infections caused by P. aeruginosa producing VIM-1 cabbapenemase in Greece. J Clin Microbiol. 2000;38:1290-92.
36.Castanheira, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a ß-lactamase gene blaGIM-1, encoding a new subclass of metallo-ß-lactamase. Antimicrob. Agents Chemother.2004;48:4654-4661.
37.Navaneeth BV, Sridaran D, Sahay D, Belwadi MR. A preliminary study on metallo beta-lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res 2000;116:264-7.
38.Migliavacca R, Docquier JD, Mognaioli C, Amicosante G, Daturi R, Lee K, Maria R, Pagani L. Simple microdilution test for detecting metallo-beta-lactamase production in Pseudomonas aeruginosa. J Clin.Microbiol.2002;40:4388-90.
39.Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A. Evaluation of a new E-test for detecting metallo-beta-lactamases in routine clinical testing. J Clin. Microbiol. 2002; 40: 2755-2759.
40.Hirakata Y, Izumikwa K, Matsuda J, Nakano M, Mine M et al. Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase producing Pseudomonas aeruginosa. Clin Infect Dis. 2003; 37:26-32.
41.Gladstone P, Rajendran P, Brahmadathan KN. Incidence of carbapenem resistant non fermenting gram negative bacilli from patients with respiratory infections in intensive care units. Indian J Med Microbiol. 2005;23:189-191.
42.Jesudason MV, Kandathil AJ, Balaji V. Comparison of two methods to detect carbapenemase and metallo-ß-lactamase production in clinical isolates. Indian J Med Res. 2005; 121: 780
43.Chacko B, Varaiya A, Dedhia B. Imipenem resistant metallo-beta-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2008; 26:398-41.
44.Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-beta-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2008; 26: 233-37.
45.Clinical and Laboratory Standards Institute. 2006. M2-A9. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
46.Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2003 Oct;41(10):4623-9.
47.Karthikeyan K Kumarasamy, Mark A Toleman, Timothy R Walsh, Jay Bagaria, Fafh ana Butt, Ravikumar Balakrishnan et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10: 597–602.
48.Allaaeddin El Salabi, Mark A. Toleman,Janis Weeks,Thomas Bruderer,Reno Frei,Timothy R. WalshFirst Report of the Metallo-β-lactamase SPM-1, in Europe. Antimicrobial agents and chemotherapy. Jan 2010; 54(1):582.
49.Fahd Manzoor, Thokar Manzoor Ahmed,Shamweel Ahmed.Extended spectrum-β-Lactamase (ESBL) producing community acquired Escherichia coli isolates & their antimicrobial susceptibility pattern in Kashmir. Journal of pharmaceutical and biomedical Sciences (JPBMS).2012;15(01)1.Available online at www.jpbms.info.
50.Peer Maroof Ahmad, Manzoor A. Thokar,Bashir A.Fomda, Kaiser A. Extended spectrum-β-Lactamase producing Klebsiella pneumonia at a tertiary care setup in Kashmir, India: Comparative phenotypic detection and antimicrobial susceptibility pattern. Reviews in Infection. 2010;1(2):124-130.
51.Ahmed K, Thokar M.A, Toboli A.S, Fomda B.A, Bashir, G, Maroof P. Extended spectrum -Beta-lactamase mediated resistance in Escherichia coli in a tertiary care hospital in Kashmir,India.African Journal of Microbiology Research.2010;4(24):2720-2728.
52.Bashir Deeba, Thokar MA, Fomda BA, et al. Detection of metallo-β-lactamase (MBL) producing Pseudomonas aeruginosa at a tertiary care hospital in Kashmir. African Journal of Microbiology Research. 2011;5(2):164–172.
53.Dar JA, Thoker MA, Khan JA, Ali A, Khan MA, Rizwan M, Bhat KH, Dar MJ, Ahmed N, Ahmad S.Molecular epidemiology of clinical and carrier strains of methicillin resistant Staphylococcus aureus (MRSA) in the hospital settings of north India. Ann Clin Microbiol Antimicrob. 2006 Sep 14; 5:22.
54.Rasmussen, B. A., and K. Bush. 1997. Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother.41:223-232.
55.McManus-Munoz, S., and M. W. Crowder. 1999. Kinetic mechanism of metallo-β-lactamase L1 from Stenotrophomonas maltophilia. Biochemistry 38:1547-1553
56.Spencer, J., A. R. Clarke, and T. R. Walsh. 2001. Novel mechanism of hydrolysis of therapeutic β-lactams by Stenotrophomonas maltophilia L1 metallo-β-lactamase. J. Biol. Chem. 276:33638-33644.
57.Wang, Z., W. Fast, and S. J. Benkovic. Direct observation of an enzyme-bound intermediate in the catalytic cycle of the metallo-β-lactamase from Bacteroides fragilis. J. Am. Chem. Soc. 1998; 120:10788-10789.
58.Page, M. I.1999. The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases. Curr. Pharm. Des. 5:895-913.
Medline
59.Page, M. I. Understanding metallo-β-lactamases. ASM News. 2002;68:217-221.
60.Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, Goto M. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol. 2000 Jan;38(1):40-3.
61.Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2001 Feb;7(2):88-91.
62.Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2002 Oct;40(10):3798-801.
63.Michael Smith. ICAAC: New MDR Gene Found in North America. http://www.medpagetoday.com/MeetingCoverage/ICAAC/22154.Published: Sep 13, 2010.
64.Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–803. [PubMed: 22915465].
65.Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54. [PMCID: PMC2786356] [PubMed: 19770275])
66.Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011; 11:355–62 [PubMed: 21478057] .
67.Travel for Surgery May Help Spread New Superbug. Last Updated: 2010-Aug-11: (Health Day)By-Randy Dotinga. http://www.lahey.org/ Departments_and_Locations/Departments/Ophthalmology/Ebsco_Content/Macular_degeneration.aspx?chunkiid=617377.
68.New antibiotic-resistant bacteria discovery, 07 April 2011, News Centre, Cardiff University, http://www.cardiff.ac.uk/news/articles/new-antibiotic-resistant-bacteria-discovery-6621.html, 16 May 2011.
69.Kusradze I, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents. 2011;38:164–8. [PubMed: 21616644]
70.Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother. 2011;66:689–92. [PubMed: 21393184]
71.Walsh TR, Toleman MA. The new medical challenge: why NDM-1? Why Indian? Expert Rev Anti Infect Ther. 2011;9:137–41. [PubMed: 21342058]
72.Sinha K. Lancet says sorry for ‘Delhi bug’ [accessed on August 25, 2011]. Available from: http://timesofindia.indiatimes.com/india/Lancet-says-sorryfor-Delhi-bug-/articleshow/7261135.cms.
73.Detection of Enterobacteriaceae isolates carrying metallobeta- lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:750. MMWR Morb Mortal Wkly Rep 2010; 59 : 750. [PubMed: 20577157]
74.Kus JV, Tadros M, Simor A, Low DE, McGeer AJ, Willey BM, et al. New Delhi metallo-ss-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. CMAJ. 2011;183:1257–61. [PMCID: PMC3153514] [PubMed: 21624908].
75.Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Begovic J, Topisirovic L, et al. Emergence of NDM-1 metallo-beta-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob Agents Chemother. 2011;55:3929–31.[PMCID: PMC3147624] [PubMed: 21646490].
76.Kusradze I, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents. 2011;38:164–8. [PubMed: 21616644].
77. D’Andrea MM, Venturelli C, Giani T, Arena F, Conte V, Bresciani P, et al. Persistent carriage and infection by multiresistant Escherichia coli ST405 producing the NDM-1 carbapenemase: a report on the first Italian cases. J Clin Microbiol. 2011;49:2755–8. [PMCID: PMC3147842] [PubMed: 21525229].
78.Kahan, F. M., H. Kropp, J. G. Sundelof, and J. Birnbaum. Thienamycin: development of imipenem-cilastatin. Antimicrob. Agents Chemother. 1983; 12(Suppl. D):S1-S35.
79.Lim, H. M., J. J. Pene, and R. W. Shaw. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 β-lactamase II structural gene. J. Bacteriol. 1988;170:2873-2878.
80.Massidda, O., G. M. Rossolini, and G. Satta. 1991. The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-β-lactamases. J. Bacteriol. 173:4611-4617.
81. Sabath LD, Abraham EP. Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem J. 1966; 98 : 11C-3.
81.Shannon K, King A, Phillips I. Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila. J Antimicrob Chemother 1986; 17:45-50.
82. Cuchural GJ Jr, Malamy MH, Tally FP. Beta-lactamase mediated imipenem resistance in Bacteroids fragilis. Antimicrob Agents Chemother 1986; 30 : 645-8.
83. Quiroga, M. I., N. Franceschini, G. M. Rossolini, G. Gutkind, G. Bonfiglio, L. Franchino, and G. Amicosante. 2000. Interaction of cefotetan and the metallo-β-lactamases produced in Aeromonas spp. and in vitro activity. Chemotherapy 46:177-183.
84.Wang, Z., W. Fast, A. M. Valentine, and S. J. Benkovic. 1999. Metallo-β-lactamase: structure and mechanism. Curr. Opin. Chem. Biol. 3:614-622.
85.Chu, Y.-W., M. Afzal-Shah, E. T. S. Houang, M.-F. I. Palepou, D. J. Lyon, N. Woodford, and D. M. Livermore. 2001. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob. Agents Chemother. 45:710-71.
86. Iyobe, S., H. Kusadokoro, J. Ozaki, N. Matsumura, S. Minami, S. Haruta, T. Sawai, and K. O'Hara. 2000. Amino acid substitution in a variant of IMP-1 metallo-β-lactamase. Antimicrob. Agents Chemother. 44:2023-2027.
87.Livermore, D. M., and N. Woodford. 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3:489-495.
88.Mehul S Chaudhari,et al. A Study of metallo-beta-lactatamase producing pseudomonas aeruginosa in clinical samples OF S.S.G. HOSPITAL. National journal of medical research. Oct–Dec 2011;1(2):60-61.
89. Lee K, YumJH, Jong D, et al. A novel acquired metallo-b-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother (in press).
90.Gales, A. C., L. C. Menezes, S. Silbert, and H. S. Sader. 2003. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J. Antimicrob. Chemother. 52:699-702.
91.Lee, K., W. G. Lee, Y. Uh, G. Y. Ha, J. Cho, and Y. Chong. 2003. VIM- and IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg. Infect. Dis. 9:868-871.
92.Arakawa, Y., M. Murakami, K. Suzuki, H. Ito, R. Wacharotayankun, S. Ohsuka, N. Kato, and M. Ohta.. A novel integron-like element carrying the metallo-β-lactamase gene blaIMP. Antimicrob. Agents Chemother. 1995;39:1612-1615.
93.Lauretti, L., M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana, and G. M. Rossolini. 1999. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.
94.Mendes, R. E., M. A. Toleman, J. Ribeiro, H. S. Sader, R. N. Jones, and T. R. Walsh. Genetic characterization of a novel metallo-β-lactamase gene, blaIMP-16: a highly divergent blaIMP with a unique genetic context. Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2004; 48:4654-4661.
Article citation:
Idris N,Mohamed FEH,Thokar MA. Rationalizing antibiotic usage in Multidrug resistant Mbl (Metallo ß lactamase)producing Pseudomonas aeruginosa infections. J Pharm Biomed Sci 2014; 04(05):382-394. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014. Idris N,Mohamed FEH,Thokar MA. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Girish Gopal1,*, Gangadhar.B. Belavadi2
Affiliation:-
1Senior Resident, Department of Pediatrics, Mysore Medical College and Research Institute, Mysore -570001, Karnataka, India
2Professor and Head, Department of Pediatrics, Bangalore Medical College and Research Institute, Bangalore - 560002, Karnataka.
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pediatrics, Mysore Medical College and Research Institute, Mysore -570001, Karnataka, India
Department of Pediatrics, Bangalore Medical College and Research Institute, Bangalore - 560002, Karnataka, India
Abstract
Epidermolysis bullosa (EB) represents a rare, heterogenous group of genetically determined skin disorders manifested by an exceptional tendency of the skin and mucous membranes to form bullae and vesicles either spontaneously or as a result of mechanical trauma/friction. EB has been classified on genetic, clinical, and histological criteria into several distinct categories of which the three major subgroups are Epidermolysis bullosa simplex, junctional epidermolysis bullosa and dystrophic epidermolysis bullosa (DEB). Both autosomal dominant and recessive forms have been described in DEB. Ineffective or absent connective tissue anchoring fibrils, resulting in a loosely bound epithelial/subepithelial connective tissue interface results in this disorder. Autosomal recessive form of DEB is a rare form of EB characterized by a generalized blistering rash involving the entire skin and almost all mucous membranes. It manifests in the early neonatal period and is usually fatal. We report a 13 day old neonate who presented to us with clinical features consistent with recessive form of DEB.
Keywords: Anchoring fibrils; bullae; epidermolysis bullosa; vesicles.
*To whom it corresponds:-
Dr. Girish Gopal;
Senior Resident,
Department of Pediatrics, Mysore Medical College & Research Institute, Irwin Road, Mysore – 570001, India
REFERENCES
1.Gorlin RJ. Epidermolysis bullosa. Oral Surg Oral Med Oral Pathol. 1971; 32:760 - 766.
2.Leverkus M, Ambach A, Hoefeld-Fegeler M. Late-onset inversa recessive dystrophic epidermolysis bul¬losa caused by glycine substitutions in collagen type VII. Br J Dermatol. 2011; 164(5): 1104 - 1106.
3.Van den Akker PC, Mellerio JE, Martinez AE. The inversa type of recessive dystrophic epidermolysis bul¬losa is caused by specific arginine and glycine substitu¬tions in type VII collagen. J Med Genet 2011; 48(3): 160 - 167.
4.Enver Turan, Mehmet Salih Gurel, Aslı Turgut Erdemir, Burcu Isık, Nurdan Yurt. Epidermolysis bullosa dystrophica inversa: A case report. J Clin Exp Invest 2012; 3(3): 412-414.
5.Milne. B, Rosales JK. Anaesthesia for correction of oesophageal stricture in a patient with recessive epidermolysis bullosa dystrophica: case report. Canad. Anaesth. Soc. J 1980; 27(2): 169-171.
6.Hashimoto I, Anton-Lamprecht I, Hofbauer M. Epider¬molysis bullosa dystrophica inversa: report on 2 sis¬ters. Hautarzt. 1976; 27(11): 532-537.
7.Crikelair, George. F, Hoehn, Robert. J, Domonkos, Anthony. N, Binkert, Barbara. BA. Plastic and Reconstructive surgery 1970; 46(1): 89-92.
8.Hashimoto I, Schnyder UW, Anton-Lamprecht I, Gedde- Dahl T, Ward S. Ultrastructural studies in epider¬molysis bullosa hereditaria. III. Recessive dystrophic types with dermolytic blistering (Hallopeau-Siemens types and inverse type). Arch Dermatol Res. 1976; 256(2):137-150.
9.Kahofer P, Bruckner-Tuderman L, Metze D, Lemmink H, Scheffer H, Smolle J. Dystrophic epidermolysis bullosa inversa with COL7A1 mutations and absence of GDA-J/F3 protein. Pediatr Dermatol. 2003;20(3): 243-248.
10.Breit R. Epidermolysis bullosa dystrophica inversa, a review and case report. Hautarzt 1979; 30(9): 471-477.
11.McGrath JA, Schofield OMV, Mayou BJ, McKee PH, Eady RAJ. Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases. Journal of Cutaneous Pathology. 1992;19(2):116-123.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Article citation:
Girish G,Belavadi GB. Dystrophic Epidermolysis Bullosa in the newborn. J Pharm Biomed Sci 2014;04(05):434-438. Available at www.jpbms.info.
Copyright © 2014 Girish G,Belavadi GB. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:
Grewal Y1,*, Evans W2
1Reader & Head, Public Health Dentistry, Rayat Bahra Dental College & Hospital (Punjab), India
2Head of the Discipline, Community Oral Health & Epidemiology, Westmead Hospital, The University of Sydney, Australia
The name of the department(s) and institution(s) to which the work should be attributed:
1. Community Oral Health & Epidemiology, Westmead Hospital, The University of Sydney, Australia
*To whom it corresponds:-
Yasmin Grewal.
House no. 1082, Sector 2, Panchkula - 134112
Haryana, India
Phone- + 91-9914512277+ 91-9914512277
Abstract:
Objective: Dental emergencies may have serious implications for infantry soldiers during military commitments as the efficiency of the unit may be compromised. The purpose of the present study was to determine the dental fitness, treatment needs, oral health behavior and beliefs of members of an Indian Army Regiment.
Material and Methods: A post deployment dental assessment of Indian Army soldiers of an infantry regiment that had served in combat was conducted in a descriptive cross-sectional study. A total of 270 subjects volunteered that included soldiers (96%) and non-commissioned officers (4%); the response rate was 89%. Eighty five percent of the population was younger than 35 years.
Results: The mean DMFT was 1.6, 2.8, and 2.7 for the age groups 20-24, 25-34, and 35 plus years respectively. Fifty nine percent were in need of restorations, 4% and 13% needed endodontic intervention and extractions respectively, and 13% were in need of periodontal treatment. Only 15% knew that AIDS could be passed from person to person via other bodily fluids.
Discussion: Poor oral health related quality of life was significantly related to a higher need for dental services, poor periodontal status, lifelong caries experience, and age. There was a substantial unmet need for restorative work and endodontic care indicating potential dental emergencies. There is a need to formulate a preventive health program that leads to a reduction in exposure to risk factors for oral diseases and measures are required to ensure that dental problems identified through annual dental examinations are treated in a timely manner.
Keywords: Indian Army; Oral Health; DMFT; CPI; AIDS; Military.
Ethical approval: Permission to conduct the study was obtained from the Indian Army Head Quarters (New Delhi, India) and approved by Human Research Ethics Committee (The University of Sydney, Australia).
REFERENCES
1.Deutsch WM. Simecek JW. Dental emergency visits of Marine Corps personnel. Mil Med. 1995;160(11):555-7.
2.Chisick MC, Piotrowski MJ. Estimated cost of dental treatment for active duty and recruit US military personnel. Mil Med. 2000;165(1):70-1.
3.Moss DL. Dental emergencies during SFOR 8in Bosnia. Mil Med. 2002;167(11): 904-906.
4.Dunn WJ. Dental emergency rates at an expeditionary medical support facility supporting Operation Enduring Freedom. Mil Med. 2004;169(5): 349-352.
5.Dunn WJ. Langsten RE, Flores S, Fandell JE. Dental emergency rates at two expeditionary medical support facility supporting Operation Enduring and Iraqi Freedom. Mil Med. 2004;169(7):510-514.
6.Richardson PS. Dental morbidity in United Kingdom Armed Forces, Iraq 2003. Mil Med. 2005;170(6):536-541.
7.Asymhr O,Grytten J. Changing trends in cries experience among male military recruits in Norway. Community Dent Oral Epidemiol. 1994;22(3):206-7.
8.Antoft P,Rambusch E, Antoft B, Christensen HW. Cries experience, dental health behaviour and social status – three comparative surveys among Danish military recruits in 1972, 1982 and 1993. Community Dent Health. 1999;16(2):80-4.
9.Rajasuo A,Murtomaa H, Meurman JH, Ankkuriniemi O. Oral health problems in Finnish conscripts. Mil Med. 1991;156(1):16-8.
10.Petersson LG, Jonsson G, Stadler LE. Samfors KA. Gleerup A. Oral status and estimated treatment need in Swedish air force conscripts. Swed Dent J. 1989;13(1-2):69-76.
11.Dale JW. Toothbrushing frequency and its relationship to dental caries and periodontal diseases. Aust Dent J. 1969;14(2):120-3.
12.Shahar Y, Carel RS. Changes in smoking patterns in young military recruits in relationship to psychosocial characteristics. Mil Med. 1991;156(9):455-61.
13.Schei E, Sogaard J. The impact of military service on young men’s smoking behaviour. Prev Med. 1994;23(2):242-8.
14.Voelker MD, Saag KG, Schwartz DA, Chrischilles E, Clarke WR, Woolson personnel. Am J Epidemiol. 2002;155(10):899-907.
15.Ministry of Health and Family Welfare, India. HIV Prevalence in India is Second Highest in World. Avaialble at: www.rxpgnews.com/medicalnews/healthcare/india/article_1564; 2005 [accessed on 25.05.05]
16.Central Intelligence Agency. CIA World Factbook 2011 - people living with the HIV virus. Avaialble at: https://www.cia.gov/library/publications/the-world-factbook/rankorder/2156rank.html; 2012 [accessed on 25.07.12]
17.China News Agency. AIDS Becomes Biggest Killer in India Army. Available at: http://www.todayszaman.com/newsDetail_getNewsById.action?load=detay&link=18745; 2005 [accessed on 25.05.05]
18.United Nations. India teams with UN to fight spread of HIV/AIDS. Available at http://www.un.org/apps/news/story.asp?NewsID=14119&Cr=hiv&Cr1=aids#.UkvyXWQpYeY;2005 [accessed on 03.05.05].
19.Chen M, Anderson RM, Barmes DE, Leclercq MH, Lyttle CS. Core questionnaires and clinical examination forms. In: Comparing Oral Health Care Systems. A Second Collaborative Study. Geneva: World Health Organization. 1997:293-300.
20.World Health Organization. Oral health surveys – basic methods, 4th edition. Geneva: 1997.
21.Gaare D, Joelmiar FA, Ouderaa FV, Rolla G. A cross-sectional study of DMFT and CPITN scores in a group of Indonesian soldiers. Scand J Dent Res. 1989;97(1):20-4.
22.Johansson AK, Johansson A, Birkhed D, Omar R, Baghdadi S, Carlsson GE. Dental erosion, soft-drink intake, and oral health in young Saudi men, and the development of a system for assessing erosive anterior tooth wear. Acta Odontol Scand. 1996;54(6):369-78.
23.Sgan-Cohen HD, Horev T, Zusman SP, Katz J, Eldad A. The prevalence and treatment of dental caries among Israeli permanent force military personnel. Mil Med. 1999;164(8):562-5.
24.Richardson PS, Mclntyre IG. Dental treatment needs of a cohort of Royal Air Force recruits over 5 years. Community Dent Health. 1996;13(1):11-6.
25.Hopcraft M, Morgan M. Dental caries experience in young adult military population. Aust Dent J. 2003;48(2):125-9.
26.Marker OT, Vigild M, Praetorius F. Oral health problems and treatment needs in Danish military personnel recruited for United Nations service. Mil Med. 1997;162(6):416-21.
27.Causes and Risk Factors of Periodontal disease. Available at: www.healthatoz.com /healthatoz/Atoz/dc/caz/enth/peri/causes.jsp; 2005 [accessed on 13.08.05]
28.Alexander DC, Pethybridge RJ. Changing trends in dental restorative treatment needs of naval recruits 1987-89-disease or diagnosis? J R Nav Med Serv. 1989;75(2):85-91.
Article citation:
Grewal Y,Evans W. Dental. Fitness of Indian Army Soldiers. J Pharm Biomed Sci 2014; 04(05):375-381. Available at www.jpbms.info.
Source of funding: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014. Grewal Y,Evans W. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Jasheena Singh1,Shruti Gupta2,*,Tejveer Singh3, Nidhi Mathur4,Priya Gupta2
Affiliation:-
1Professor and Head, Department of Pedodontics, Maharana Pratap College of Dentistry & Research Centre, Gwalior, India
2Senior Lecturer, Department of Oral Pathology, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
3Senior Lecturer, Department of Oral Surgery, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
4Professor and Head, Department of Pathology, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pedodontics, Maharana Pratap College of Dentistry & Research Centre, Gwalior, India
Department of Oral Pathology, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
Abstract
Lesions on tongue include a diverse group of developmental, reactive, neoplastic lesions and various systemic pathologies with oral manifestations. They often present diagnostic challenges because they mimic various groups of pathologic processes and thus necessitating the correlation of clinical and histopathological findings for accurate diagnosis. Thus, here we present a case of 14 year old male with growth on tongue along with emphasis on the differential diagnosis of tongue lesions.
Keywords: Fibroepithelial hyperplasia, Irritational fibroma, reactive.
*To whom it corresponds:-
Dr. Shruti Gupta.
H.No. 166, Old P.L.A Sector, Hisar, Haryana-125001,India
Contact no:+91-9465288400
Article citation:
Singh J, Gupta S, Singh T, Mathur N, Gupta P. Tongue Lesions: A Diagnostic Challenge. J Pharm Biomed Sci 2014;04(05):459-462. Available at www.jpbms.info.
REFERENCES
1.Reamy BV, Derby R, Bunt CW. Common tongue conditions in primary care. Am Fam Physician 2010;81:627-34.
2.Laskin DM, Giglio JA, Rippert ET. Differential diagnosis of tongue lesion. Quintessence Int 2003;34:331-42.
3.Prasanna JS, Sehrawat S. Fibroepithelial hyperplasia: rare, selflimiting condition- two case reports. J Adv Oral Research 2011;2:63-70.
4.Regezi JA, Sciubba JJ, Jordan RCK. Oral pathology: clinical pathologic correlations.6th ed. St. Louis, Missouri, Saunders;2012.
5.Shafer, Hine, Levy. Shafer’s textbook of oral pathology. 6th ed. India: Elsevier;2009.
6.Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and Maxillofacial Pathology. 3rd ed. Missouri: Saunders; 2009.
7.Tyldesley WR. Inflammatory overgrowths and neoplasms. Br Dent J 1974;136:111-6.
8.McNally MA, Langlais RP. Conditions peculiar to the tongue. Dermatol Clin 1996; 14:257-72.
9.Pedron GI, Ramalho KM, Moreira LA, de Freitas PM. Association of two lasers in the treatment of traumatic fibroma: excision with Nd: YAP laser and photobiomodulation using InGaAIP: a case report. J Oral Laser Applications 2009;9:49-53.
Copyright © 2014 Singh J, Gupta S, Singh T, Mathur N, Gupta P. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Competing interest /Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.